At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 7 enrolled
Drug / intervention
18F-FSPG +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Study of the Role of 18F-FSPG PET/CT Imaging for Cancer Patients Receiving Therapy
In Brief
A Phase 2 clinical trial evaluating 18F-FSPG and 18F-FDG for B-Cell Neoplasm and 15 related conditions. Completed, enrolled 7 participants across 1 site.
Detailed Summary
The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG used before and after treatment to diagnose, predict, and evaluate response to therapy in patients with a wide variety of metastatic cancers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-Cell Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Renal Cell Cancer, Progesterone Receptor Negative, Stage III Mesothelioma, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Mesothelioma, Stage IV Non-Small Cell Lung Cancer, Stage IV Renal Cell Cancer, Triple-Negative Breast Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJul 2015
First PostedNov 2015
Primary CompletionDec 2016
TodayJul 2026
First PostedNov 6, 2015
Enrollment StartJul 1, 2015
Primary CompletionDec 14, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.7 years ago
Interventions
18F-FSPGdrug
Administered intravenously (IV)
18F-FDGdrug
Administered intravenously (IV)